MPE interviews experts about different aspects of the CARAMBA clinical trial

As part of the Horizon 2020 CARAMBA project, Myeloma Patients Europe (MPE) interviewed experts on different aspects of the CARAMBA clinical trial: manufacturing process, safety updates, and immune monitoring. The videos were filmed during the ASH annual meeting in December 2022. The CARAMBA project is a phase I/II clinical trial investigating innovative immunotherapy for treating myeloma, known as Chimeric Antigen Receptor T-cell therapy (CAR-T). Through strategic collaboration with a wide range of stakeholders, including MPE,…

MPE participated in the discussion panel of the documentary premiere

Listen the voice of myeloma patients in documentary “My myeloma: ready for the steps ahead”

March is Multiple Myeloma Awareness Month. This incurable disease affects increasingly young adult generation. In Europe, more than 50.900 people were diagnosed with myeloma in 2020[1].   Patient organisations from Central and Eastern Europe (CEE) have joined forces to create the documentary My myeloma: ready for the steps ahead, which premiered on 21th of March 2023 in Ljubljana, Slovenia. The premiere was attended by patient representatives, patient organisations, healthcare professionals and media representatives, who expressed…

Picture of the awards given at the AMILO conference

Happy anniversary AMILO!

One of the MPE Spanish members, the Spanish Amyloidosis Association (AMILO), last month celebrated its fifth anniversary by recognising the support and help other organisations have given them during these five years. MPE is pleased and proud to receive this recognition from AMILO at such an important event for our member. Along with MPE, other important national and international organisations were awarded, like the Amyloidosis Alliance and the Spanish Society of Hematology, represented by its…

T2EVOLVE and QUALITOP launch European patient survey on CAR-T treatment

THE IMI T2EVOLVE Project and the Horizon 2020 QUALITOP Project have launched a European patient survey on CAR-T treatment. The survey aims to inform on patient and carer experiences and challenges of receiving CAR-T and to identify information needs and gaps across Europe. The results of the survey will be used for research purposes and published anonymously on project partner websites as well as in academic journals.   The T2EVOLVE-QUALITOP European patient survey on CAR-T…

Talquetamab generates high response rate in patients with hard-to-treat myeloma

NEW ORLEANS. New research being presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition focuses on talquetamab in patients with Relapsed/Refractory myeloma. In an early-phase trial, nearly three-quarters of patients who received talquetamab, a first-in-class experimental immunotherapy for myeloma, saw a significant reduction in cancer burden within a few months. The study participants had all been previously treated with at least three different therapies without achieving lasting remission, suggesting talquetamab could offer new…

Horizon Europe research project looks to improve the affordability and sustainability of innovative health technologies

  Starting in December 2022, the HORIZON-funded project ASCERTAIN (Affordability and Sustainability improvements through new pricing, Cost- Effectiveness and Reimbursement models to Appraise innovative health technologies) will address the need of patients, physicians, payers, regulators, and manufacturers to improve the affordability and accessibility to innovative health technologies (including pharmaceuticals) in Europe. Affording newly approved innovative health technologies (IHTs) is challenging in many health systems.